Antiaging Quantum Living Inc (AAQL)

[KALANDRO]

ACHN$$$ Fri Jun 12, 9:49AM UTC
http://www.barchart.com/headlines/story/8706378/paroxysmal-nocturnal-hemoglobinuria-pipeline-review-h1-2015-7-companies-10-drug-profiles

[KALANDRO]

http://www.barchart.com/headlines/story/8706378/paroxysmal-nocturnal-hemoglobinuria-pipeline-review-h1-2015-7-companies-10-drug-profiles

[maverick_1]

When Wall St analysts are on the wrong side of the strategic issue as I pointed out in my first post:

maverick_1 Sunday, 03/08/15 02:46:40 PM
Re: None
Post # of 708
Strategic Assessment of why BMY'(or other Big Pharma) need to participate in a crowded, price competitive Hep C mkt is IMHO the key to it being a winner as ACHN is late to party and no collaboration.

HEP C Area WAS ripe.
ACHN has appreciated 5X from 52 wk lows
GILD and Abbie dominate and pricing pressures will continue
Does BMY (or other Big Pharma) want or need to further address HEP C and what are the catalysts that make strategic investment sense to BMY etc.

So altho ACHN's recent data is impressive but limited and I AM A NOVICE in ACHN that is why I have avoided ACHN in last two months despite institutional owners (not a significant holding of any instl IMHO). Looks controversial.

My preference: Better odds with investment success when either or both are at play:

EARLY in Industry Acceptance and/or Institutional acceptance

versus the current:

Industry sector has mushroomed and finds itself subject to pricing pressures induced by insurers and dealing with two entrenched key players.

ACHN may be a good trade for nimble ones, but better investment IF the above is laid out.

This post prompted by involvement of a few notable NWBO brethen.

on this board that was validated by MARKET RESPONSE to JNJ/ACHN deal recognizing that ALIO Rx a previous acquired co by JNJ Jansen for $1.7 Bln BUYOUT that underscores also what DewDiligence has also indicated: A WORKOUT vs a buyout.

SHS keep on making new short term lows and any "rally" is snuffed out.

Don't forget the LARGE capital raise pre-Spring 2015 @ $10.25 done at an already significant discount to market then: FEW 2nd's with that Wall St. following have been underwater like ACHN.

Sadly yet another of Pyrrhn rec's going SOUTH: only exception of a handful was CLDX.

[north40000]

Chart not working well lately....$8.68 now in a general biotech sell-off.

[Basin Street Blues]

Achillion Pharmaceuticals Inc forms bullish "Bottom Triangle"
chart pattern
Recognia has detected a "Bottom Triangle" chart pattern formed on Achillion Pharmaceuticals Inc (ACHN on NASDAQ). This bullish signal indicates that the price may rise from the close of 9.59 to the range of 11.70 - 12.10. The pattern formed over 24 days which is roughly the period of time in which the target price range may be achieved.
Achillion Pharmaceuticals Inc has a current support price of 9.41 and a resistance level of 9.62.

A Bottom Triangle/Wedge is considered a bullish signal, marking a possible reversal of the current downtrend. The pattern is formed during a downtrend and shows two trendlines converging. The technical event occurs when the price breaks upward out of the Triangle/Wedge formation and closes above the upper trendline, thereby confirming the pattern.

This bullish pattern can be seen on the following chart and was detected by Recognia's proprietary pattern recognition technology.

Click here for chart with pattern

[maverick_1]

Adding more salt to the JNJ/ACHN wound

My initial assessment strategically was closest to what transpired recently with the terms of the JNJ/ACHN collaboration than what many had opined since the start of 2015.

Clearly the fly in the ointment was JNJ's Sept 2014 $1.7 bln acquisition of privately held Alios Therapeutics.

Adding more salt to the JNJ/ACHN wound is the below excerpt's from today's Seeking Alpha http://seekingalpha.com/article/3203006-gilead-merck-and-achillion-j-and-j-square-off-in-an-hcv-nuclear-showdown

By acquiring Alios last year and negotiating a deal with Achillion this week, JNJ has put itself in a position to be a contender with the nucleotide AL-335 and NS5A inhibitor ACH 3102, although they are far behind and have the highest risks. Given the IP risks with ACH 3422 and the relatively poor performance vs. Sovaldi in mono-treatment, I don't expect JNJ to advance Achillion's nucleotide. If JNJ was interested in ACH 3422, they would have purchased ACHN and the price would have been much higher.

Achillion’s nuke ACH 3422 suffers from poor bio-availability, has a tenuous IP position, and a slow pace of development

[GreenThumb Investor]

Loaded up for massive run

Johnson & Johnson will develop and sell Achillion Pharmaceuticals Inc.'s hepatitis C drugs and invest $225 million in Achillion, in a combined deal valued at about $1.1 billion, the companies said on Tuesday.

[GreenThumb Investor]

Big move coming north.

[DewDiligence]

Please see #msg-113833772. Regards, Dew

[magicmk]

DewDiligence,

Can you tell me how this caps the upside? Looks like J&J bought at a premium to infuse cash into the company. Wasn't it just a couple of months ago the company did a secondary at $10 that was gobbled up?

Please take this as a knowledge question. I want to see if my thinking is incorrect.

Thanks in advance,

GLTA

[KingDMC]

You'd think this would be worth $12.25.

[KingDMC]

I'm in the same boat!

[bullrider2]

I don't know whether too short this one or buy it.

[bullrider2]

GOING back up!!

[bullrider2]

I agree you. I'am very glad I didn't hop on this one like the $avon#. Woo wee this is very bad.

[DewDiligence]

It's not bad, but it caps the upside. A lot of ACHN investors were expecting more.

p.s. Note how the big pumpers of the past few days are suddenly gone.

[crudeoil24]

Tank City!!!!!

[KingDMC]

This is bad???

[DewDiligence]

#msg-113830844.

[KingDMC]

Why all the selling??

[KingDMC]

Awesome

[crudeoil24]

ACHN reopens in three minutes. HUGE NEWS > JNJ.

[DewDiligence]

JNJ licenses ACHN’s HCV pipeline—buys 18.4M shares @$12.25/sh (a 15% premium to today’s closing price):

http://finance.yahoo.com/news/janssen-enters-worldwide-collaboration-achillion-200500889.html

Achillion Pharmaceuticals, Inc. announced today that it has entered into a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize one or more of Achillion's lead hepatitis C virus (HCV) assets which include ACH-3102, ACH-3422, and sovaprevir.

Under the terms of the agreement, Achillion will grant Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion's HCV assets. Achillion is eligible to receive a number of payments based upon achievement of specified development, regulatory and sales milestones. Achillion is also eligible to receive tiered royalty percentages between mid-teens and low-twenties based upon future worldwide sales. Janssen will be responsible for all of the development costs within the collaboration and all subsequent costs related to commercialization of the HCV assets.

…in an equity transaction separate to the exclusive license and collaboration arrangement, Johnson & Johnson Innovation…will invest $225 million in Achillion and, in return, receive approximately 18.4 million newly issued, unregistered shares of Achillion at a price of $12.25 per share.

Stock is currently halted.

CC at 5pm ET.

[frontiers]

ACHN:

trust me when I tell you something great is about to happen for ACHN

As a long time investor in ACHN, I like your call. I do know there's a lot of pending news due out soon -- (1) ACH 3422 trial results in GT2 and GT3, (2) Sparta trials on 3422/3102 doublet 12/8/6 week treatment starting in June, (3) new tablet formulations for all 3 agents (3422, 3102, sovaprevir) for ease of use by patients, (4) competitor's drug regimens not faring so well for 6 week treatment, ... and many other items, which we will hear about in due course. It's all good!

What are your thoughts on something great for ACHN?

You did mention a possible GILD buyout. I see a buyout by any of the other Hep C players (MRK or ABBV or BMY or J&J) being equally likely.

[KingDMC]

When was it scheduled for?

[DewDiligence]

Something might be happening, but it's not necessarily a GILD buyout, which is what you asserted.

[Kraken3]

I have no question that you do your DewDiligence but I have been doing this probably longer than you have been alive. You don't see this kind of spike in Call options on a stock with a heavy short interest unless somebody in the know, knows something great. May not happen tomorrow or even next week but trust me when I tell you something great is about to happen for ACHN.

[Kraken3]

How so?

[DewDiligence]

GILD buyout of ACHN almost a certainty at this point.

That's BS.

[Kraken3]

GILD buyout of ACHN almost a certainty at this point. Benefits GILD the most.

[protagonist12]

ACHN canceled appearance at health care conference, rumor of buyout offers on the table. The idea is that once buyout talks have started they don't need to sell their data at that point.

[stocktrademan]

$ACHN recent news/filings

bullish

## source: finance.yahoo.com

Fri, 15 May 2015 17:04:10 GMT ~ ACHILLION PHARMACEUTICALS INC Financials


read full: http://finance.yahoo.com/q/is?s=achn
*********************************************************

Mon, 11 May 2015 00:11:51 GMT ~ 10-Q for Achillion Pharmaceuticals, Inc.


read full: http://www.companyspotlight.com/routers/headline/19045/10004/6514507?cp_code=YAH1&1431303111
*********************************************************

Thu, 07 May 2015 11:37:21 GMT ~ Achillion Reports First Quarter 2015 Financial Results

[at noodls] - NEW HAVEN, Conn., May 7, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended March 31, 2015. For the first quarter of 2015, ...

read full: http://www.noodls.com/view/3A148F4BED3C88F294B795BEB87E169C64DA721C
*********************************************************

Thu, 07 May 2015 11:32:48 GMT ~ ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements


read full: http://biz.yahoo.com/e/150507/achn8-k.html
*********************************************************

Thu, 07 May 2015 10:16:01 GMT ~ Achillion reports 1Q loss


read full: http://sg.finance.yahoo.com/news/achillion-reports-1q-loss-101601487.html
*********************************************************

$ACHN charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$ACHN company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ACHN/company-info
Ticker: $ACHN
OTC Market Place: Not Available
CIK code: not found
Company name: Achillion Pharmaceuticals, Inc.
Incorporated In: DE, USA

Business Description: OTC Markets | Official site of the OTCQX, OTCQB and OTC Pink Marketplaces featuring Free Stock & Bond Quotes, Trade Prices, Chart, Financials and Company News & Information for Investors, Companies and Traders - OTCMarkets.com (window.NREUM||(NREUM={})).loader_config={xpid:"UwMGWVdSGwQIU1RQAgQ="};window.NREUM||(NREUM={}),__nr_require=function(t,e,n){function r(n){if(!e[n]){var o=e[n]={exports:{}};t[n][0].call(o.exports,function(e){var o=t[n][1][e];return r(o?o:e)},o,o.exports)}return e[n].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;od;d++)c[d].apply(u,n);return u}function a(t,e){f[t]=s(t).concat(e)}function s(t){return f[t]||[]}function c(){return n(e)}var f={};return{on:a,emit:e,create:c,listeners:s,_events:f}}function r(){return{}}var o="nr@context",i=t("gos");e.exports=n()},{gos:"7eSDFh"}],ee:[function(t,e){e.exports=t("QJf3ax")},{}],3:[function(t){function e(t){try{i.console&&console.log(t)}catch(e){}}var n,r=t("ee"),o=t(1),i={};try{n=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(i.console=!0,-1!==n.indexOf("dev")&&(i.dev=!0),-1!==n.indexOf("nr_dev")&&(i.nrDev=!0))}catch(a){}i.nrDev&&r.on("internal-error",function(t){e(t.stack)}),i.dev&&r.on("fn-err",function(t,n,r){e(r.stack)}),i.dev&&(e("NR AGENT IN DEVELOPMENT MODE"),e("flags: "+o(i,function(t){return t}).join(", ")))},{1:23,ee:"QJf3ax"}],4:[function(t){function e(t,e,n,i,s){try{c?c-=1:r("err",[s||new UncaughtException(t,e,n)])}catch(f){try{r("ierr",[f,(new Date).getTime(),!0])}catch(u){}}return"function"==typeof a?a.apply(this,o(arguments)):!1}function UncaughtException(t,e,n){this.message=t||"Uncaught error with no additional information",this.sourceURL=e,this.line=n}function n(t){r("err",[t,(new Date).getTime()])}var r=t("handle"),o=t(6),i=t("ee"),a=window.onerror,s=!1,c=0;t("loader").features.err=!0,t(5),window.onerror=e;try{throw new Error}catch(f){"stack"in f&&(t(1),t(2),"addEventListener"in window&&t(3),window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&!/CriOS/.test(navigator.userAgent)&&t(4),s=!0)}i.on("fn-start",function(){s&&(c+=1)}),i.on("fn-err",function(t,e,r){s&&(this.thrown=!0,n(r))}),i.on("fn-end",function(){s&&!this.thrown&&c>0&&(c-=1)}),i.on("internal-error",function(t){r("ierr",[t,(new Date).getTime(),!0])})},{1:10,2:9,3:7,4:11,5:3,6:24,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],5:[function(t){t("loader").features.ins=!0},{loader:"G9z0Bl"}],6:[function(t){function e(){}if(window.performance&&window.performance.timing&&window.performance.getEntriesByType){var n=t("ee"),r=t("handle"),o=t(1),i=t(2);t("loader").features.stn=!0,t(3),n.on("fn-start",function(t){var e=t[0];e instanceof Event&&(this.bstStart=Date.now())}),n.on("fn-end",function(t,e){var n=t[0];n instanceof Event&&r("bst",[n,e,this.bstStart,Date.now()])}),o.on("fn-start",function(t,e,n){this.bstStart=Date.now(),this.bstType=n}),o.on("fn-end",function(t,e){r("bstTimer",[e,this.bstStart,Date.now(),this.bstType])}),i.on("fn-start",function(){this.bstStart=Date.now()}),i.on("fn-end",function(t,e){r("bstTimer",[e,this.bstStart,Date.now(),"requestAnimationFrame"])}),n.on("pushState-start",function(){this.time=Date.now(),this.startPath=location.pathname+location.hash}),n.on("pushState-end",function(){r("bstHist",[location.pathname+location.hash,this.startPath,this.time])}),"addEventListener"in window.performance&&(window.performance.addEventListener("webkitresourcetimingbufferfull",function(){r("bstResource",[window.performance.getEntriesByType("resource")]),window.performance.webkitClearResourceTimings()},!1),window.performance.addEventListener("resourcetimingbufferfull",function(){r("bstResource",[window.performance.getEntriesByType("resource")]),window.performance.clearResourceTimings()},!1)),document.addEventListener("scroll",e,!1),document.addEventListener("keypress",e,!1),document.addEventListener("click",e,!1)}},{1:10,2:9,3:8,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],7:[function(t,e){function n(t){i.inPlace(t,["addEventListener","removeEventListener"],"-",r)}function r(t){return t[1]}var o=(t(1),t("ee").create()),i=t(2)(o),a=t("gos");if(e.exports=o,n(window),"getPrototypeOf"in Object){for(var s=document;s&&!s.hasOwnProperty("addEventListener");)s=Object.getPrototypeOf(s);s&&n(s);for(var c=XMLHttpRequest.prototype;c&&!c.hasOwnProperty("addEventListener");)c=Object.getPrototypeOf(c);c&&n(c)}else XMLHttpRequest.prototype.hasOwnProperty("addEventListener")&&n(XMLHttpRequest.prototype);o.on("addEventListener-start",function(t){if(t[1]){var e=t[1];"function"==typeof e?this.wrapped=t[1]=a(e,"nr@wrapped",function(){return i(e,"fn-",null,e.name||"anonymous")}):"function"==typeof e.handleEvent&&i.inPlace(e,["handleEvent"],"fn-")}}),o.on("removeEventListener-start",function(t){var e=this.wrapped;e&&(t[1]=e)})},{1:24,2:25,ee:"QJf3ax",gos:"7eSDFh"}],8:[function(t,e){var n=(t(2),t("ee").create()),r=t(1)(n);e.exports=n,r.inPlace(window.history,["pushState"],"-")},{1:25,2:24,ee:"QJf3ax"}],9:[function(t,e){var n=(t(2),t("ee").create()),r=t(1)(n);e.exports=n,r.inPlace(window,["requestAnimationFrame","mozRequestAnimationFrame","webkitRequestAnimationFrame","msRequestAnimationFrame"],"raf-"),n.on("raf-start",function(t){t[0]=r(t[0],"fn-")})},{1:25,2:24,ee:"QJf3ax"}],10:[function(t,e){function n(t,e,n){t[0]=o(t[0],"fn-",null,n)}var r=(t(2),t("ee").create()),o=t(1)(r);e.exports=r,o.inPlace(window,["setTimeout","setInterval","setImmediate"],"setTimer-"),r.on("setTimer-start",n)},{1:25,2:24,ee:"QJf3ax"}],11:[function(t,e){function n(){f.inPlace(this,p,"fn-")}function r(t,e){f.inPlace(e,["onreadystatechange"],"fn-")}function o(t,e){return e}function i(t,e){for(var n in t)e[n]=t[n];return e}var a=t("ee").create(),s=t(1),c=t(2),f=c(a),u=c(s),d=window.XMLHttpRequest,p=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"];e.exports=a,window.XMLHttpRequest=function(t){var e=new d(t);try{a.emit("new-xhr",[],e),u.inPlace(e,["addEventListener","removeEventListener"],"-",o),e.addEventListener("readystatechange",n,!1)}catch(r){try{a.emit("internal-error",[r])}catch(i){}}return e},i(d,XMLHttpRequest),XMLHttpRequest.prototype=d.prototype,f.inPlace(XMLHttpRequest.prototype,["open","send"],"-xhr-",o),a.on("send-xhr-start",r),a.on("open-xhr-start",r)},{1:7,2:25,ee:"QJf3ax"}],12:[function(t){function e(t){var e=this.params,r=this.metrics;if(!this.ended){this.ended=!0;for(var i=0;c>i;i++)t.removeEventListener(s,this.listener,!1);if(!e.aborted){if(r.duration=(new Date).getTime()-this.startTime,4===t.readyState){e.status=t.status;var a=t.responseType,f="arraybuffer"===a||"blob"===a||"json"===a?t.response:t.responseText,u=n(f);if(u&&(r.rxSize=u),this.sameOrigin){var d=t.getResponseHeader("X-NewRelic-App-Data");d&&(e.cat=d.split(", ").pop())}}else e.status=0;r.cbTime=this.cbTime,o("xhr",[e,r,this.startTime])}}}function n(t){if("string"==typeof t&&t.length)return t.length;if("object"!=typeof t)return void 0;if("undefined"!=typeof ArrayBuffer&&t instanceof ArrayBuffer&&t.byteLength)return t.byteLength;if("undefined"!=typeof Blob&&t instanceof Blob&&t.size)return t.size;if("undefined"!=typeof FormData&&t instanceof FormData)return void 0;try{return JSON.stringify(t).length}catch(e){return void 0}}function r(t,e){var n=i(e),r=t.params;r.host=n.hostname+":"+n.port,r.pathname=n.pathname,t.sameOrigin=n.sameOrigin}if(window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&!/CriOS/.test(navigator.userAgent)){t("loader").features.xhr=!0;var o=t("handle"),i=t(2),a=t("ee"),s=["load","error","abort","timeout"],c=s.length,f=t(1);t(4),t(3),a.on("new-xhr",function(){this.totalCbs=0,this.called=0,this.cbTime=0,this.end=e,this.ended=!1,this.xhrGuids={}}),a.on("open-xhr-start",function(t){this.params={method:t[0]},r(this,t[1]),this.metrics={}}),a.on("open-xhr-end",function(t,e){"loader_config"in NREUM&&"xpid"in NREUM.loader_config&&this.sameOrigin&&e.setRequestHeader("X-NewRelic-ID",NREUM.loader_config.xpid)}),a.on("send-xhr-start",function(t,e){var r=this.metrics,o=t[0],i=this;if(r&&o){var f=n(o);f&&(r.txSize=f)}this.startTime=(new Date).getTime(),this.listener=function(t){try{"abort"===t.type&&(i.params.aborted=!0),("load"!==t.type||i.called===i.totalCbs&&(i.onloadCalled||"function"!=typeof e.onload))&&i.end(e)}catch(n){try{a.emit("internal-error",[n])}catch(r){}}};for(var u=0;c>u;u++)e.addEventListener(s,this.listener,!1)}),a.on("xhr-cb-time",function(t,e,n){this.cbTime+=t,e?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof n.onload||this.end(n)}),a.on("xhr-load-added",function(t,e){var n=""+f(t)+!!e;this.xhrGuids&&!this.xhrGuids[n]&&(this.xhrGuids[n]=!0,this.totalCbs+=1)}),a.on("xhr-load-removed",function(t,e){var n=""+f(t)+!!e;this.xhrGuids&&this.xhrGuids[n]&&(delete this.xhrGuids[n],this.totalCbs-=1)}),a.on("addEventListener-end",function(t,e){e instanceof XMLHttpRequest&&"load"===t[0]&&a.emit("xhr-load-added",[t[1],t[2]],e)}),a.on("removeEventListener-end",function(t,e){e instanceof XMLHttpRequest&&"load"===t[0]&&a.emit("xhr-load-removed",[t[1],t[2]],e)}),a.on("fn-start",function(t,e,n){e instanceof XMLHttpRequest&&("onload"===n&&(this.onload=!0),("load"===(t[0]&&t[0].type)||this.onload)&&(this.xhrCbStart=(new Date).getTime()))}),a.on("fn-end",function(t,e){this.xhrCbStart&&a.emit("xhr-cb-time",[(new Date).getTime()-this.xhrCbStart,this.onload,e],e)})}},{1:"XL7HBI",2:13,3:11,4:7,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],13:[function(t,e){e.exports=function(t){var e=document.createElement("a"),n=window.location,r={};e.href=t,r.port=e.port;var o=e.href.split("://");return!r.port&&o[1]&&(r.port=o[1].split("/")[0].split("@").pop().split(":")[1]),r.port&&"0"!==r.port||(r.port="https"===o[0]?"443":"80"),r.hostname=e.hostname||n.hostname,r.pathname=e.pathname,r.protocol=o[0],"/"!==r.pathname.charAt(0)&&(r.pathname="/"+r.pathname),r.sameOrigin=!e.hostname||e.hostname===document.domain&&e.port===n.port&&e.protocol===n.protocol,r}},{}],14:[function(t,e){function n(t){return function(){r(t,[(new Date).getTime()].concat(i(arguments)))}}var r=t("handle"),o=t(1),i=t(2);"undefined"==typeof window.newrelic&&(newrelic=window.NREUM);var a=["setPageViewName","addPageAction","setCustomAttribute","finished","addToTrace","inlineHit","noticeError"];o(a,function(t,e){window.NREUM[e]=n("api-"+e)}),e.exports=window.NREUM},{1:23,2:24,handle:"D5DuLP"}],"7eSDFh":[function(t,e){function n(t,e,n){if(r.call(t,e))return t[e];var o=n();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(t,e,{value:o,writable:!0,enumerable:!1}),o}catch(i){}return t[e]=o,o}var r=Object.prototype.hasOwnProperty;e.exports=n},{}],gos:[function(t,e){e.exports=t("7eSDFh")},{}],handle:[function(t,e){e.exports=t("D5DuLP")},{}],D5DuLP:[function(t,e){function n(t,e,n){return r.listeners(t).length?r.emit(t,e,n):(o[t]||(o[t]=[]),void o[t].push(e))}var r=t("ee").create(),o={};e.exports=n,n.ee=r,r.q=o},{ee:"QJf3ax"}],id:[function(t,e){e.exports=t("XL7HBI")},{}],XL7HBI:[function(t,e){function n(t){var e=typeof t;return!t||"object"!==e&&"function"!==e?-1:t===window?0:i(t,o,function(){return r++})}var r=1,o="nr@id",i=t("gos");e.exports=n},{gos:"7eSDFh"}],G9z0Bl:[function(t,e){function n(){var t=p.info=NREUM.info,e=f.getElementsByTagName("script")[0];if(t&&t.licenseKey&&t.applicationID&&e){s(d,function(e,n){e in t||(t[e]=n)});var n="https"===u.split(":")[0]||t.sslForHttp;p.proto=n?"https://":"http://",a("mark",["onload",i()]);var r=f.createElement("script");r.src=p.proto+t.agent,e.parentNode.insertBefore(r,e)}}function r(){"complete"===f.readyState&&o()}function o(){a("mark",["domContent",i()])}function i(){return(new Date).getTime()}var a=t("handle"),s=t(1),c=(t(2),window),f=c.document,u=(""+location).split("?")[0],d={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-632.min.js"},p=e.exports={offset:i(),origin:u,features:{}};f.addEventListener?(f.addEventListener("DOMContentLoaded",o,!1),c.addEventListener("load",n,!1)):(f.attachEvent("onreadystatechange",r),c.attachEvent("onload",n)),a("mark",["firstbyte",i()])},{1:23,2:14,handle:"D5DuLP"}],loader:[function(t,e){e.exports=t("G9z0Bl")},{}],23:[function(t,e){function n(t,e){var n=[],o="",i=0;for(o in t)r.call(t,o)&&(n=e(o,t[o]),i+=1);return n}var r=Object.prototype.hasOwnProperty;e.exports=n},{}],24:[function(t,e){function n(t,e,n){e||(e=0),"undefined"==typeof n&&(n=t?t.length:0);for(var r=-1,o=n-e||0,i=Array(0>o?0:o);++r

$ACHN share structure

## source: otcmarkets.com

Market Value: $1,124,857,743 a/o May 15, 2015
Shares Outstanding: 117,558,885 a/o May 01, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001

$ACHN extra dd links

Company name: Achillion Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ACHN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ACHN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ACHN+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ACHN/news - http://finance.yahoo.com/q/h?s=ACHN+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ACHN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ACHN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ACHN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ACHN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Achillion+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Achillion+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Achillion+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ACHN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ACHN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ACHN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ACHN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ACHN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ACHN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ACHN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ACHN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ACHN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ACHN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ACHN+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ACHN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ACHN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ACHN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ACHN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ACHN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ACHN/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ACHN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ACHN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ACHN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ACHN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ACHN



$ACHN DD Notes ~ http://www.ddnotesmaker.com/ACHN

[DewDiligence]

Unlikely, IMO. Sovaprevir remains on partial FDA clinical hold for doses above 200mg/day.

[MasterofCoin15]

Sovapravir going to take over HCV treatment guidelines very soon!

[buyback42]

JMP Note:

Achillion Pharmaceuticals' Phase 2 Sparta doublet trial start with HCV nuc on track, while competitive data at the European liver meeting (EASL) suggest slightly lower bar for ACHN; reiterate our Market Outperform rating and $24 price target. At the European liver conference (EASL) in Vienna, we met with ACHN management and learned of the following updates on the timing of the data from ACHN’s Hepatitis C portfolio: 1) the initiation of the Sparta doublet (ACH-3422 + ACH-3102 for a six-, eight- and 12-week duration) is imminent; 2) data from Sparta doublet are expected towards YE15 (likely after AASLD) with data from all three durations likely to be announced simultaneously; 4) we expect the Sparta triplet study (ACH3102+ACH-3422+sovaprevir) to start at the end of 2015/early 2016 as ACHN awaits the data readout from both Sparta doublet and Ithaca triplet to inform the study. Data presented at EASL for GILD’s triple combination, focused on shortening therapy for the treatment of HCV, suggests a lower competitive bar for ACHN (four-week duration a no-go, while a six-week duration would be deemed "ok" for easy to treat patients). It appears that with their next wave of HCV regimens, drug developers continue to tailor treatment duration according to disease severity evaluating the six- to eight-week range with triple combinations. We continue to view ACHN’s strategy to shorten duration to six weeks as risky with its dual regimen, but 12 weeks or even eight weeks may be achievable and the first set of data for ACHN should become available at YE15.

[Basin Street Blues]

Its a 5 page full critique of Hep C at EASL , I posted the head line because its what I believed prior to the article .

If anyone wants to read the rest its $1500 a month 3 months minimum subscription . 330,000 subscribers do pay so I`d suggest its worth the money ..

[DewDiligence]

No insights in that write-up that haven’t been discussed ad nauseam elsewhere.

Is stuff like that all people get for a paid subscription to Bloomberg Pro?

[Basin Street Blues]

Bloomberg Professional Just out

Gilead, Achillion Race for New Hepatitis CAnalyst Asthika Goonewardene Dashboard: Biotech, Global (BI BIOTG)Apr 27, 2015 12:36

Achillion and Gilead, competing for next-generation Hepatitis C drugs, presentdata at the European Association for the Sof the Liver (EASL) conference. Both are aggressively pursuing new regimens and combining different classes of drugs that attack replication of the Hep C virus. Of interest was Achillion's Nucleotide NS5B inhibitor, known as Nuc, and next-generation Nonstructural Protein 5inhibitors (NS5A) from both companies.Gilead's data was underwhelming, so Achillion may be winning this contest.
Data presented for Achillion's ACH-3422 underpinned its promise in treating Hep C at last week's EAS15 conference. The Nuc-class drug reduced viral loads even at the end of 14-day therapy, suggesting more room for eradication if the drug is continued. The viral load cleared as a proportion of the baseline also fueled hopes that the duration of therapy can be reduced in multi-drug combinations. Still, eradication while on therapy is insufficient; the drug must also keep the virus suppressed after treatment.

[DewDiligence]

[OT ARWR]—See my reply in #msg-112665052.

[maverick_1]

ARWR: Arrowhead cleared to proceed to Phase 2b for hep B candidate

The FDA gives the green light to Arrowhead Research (NASDAQ:ARWR) to initiate a Phase 2b study of ARC-520 for the treatment of chronic hepatitis B infection. The study, called Heparc-2004, will involved 12 patients, eight will receive 1 mg/kg of ARC-520 and four will receive placebo.The trial is designed to assess multiple doses of ARC-520 (2 mg/kg and 4 mg/kg) but FDA has a partial clinical hold in place until it reviews data from the 1 mg/kg arm.The company expects to begin patient enrollment in ~1 month.Previously: Arrowhead drops after FDA partial clinical hold on hep B candidate (Jan. 12)

Coupled with my 1st post on ACHN, this is why I've preferred ARWR over the last two months for a whole host of portfolio reasons just like what is evolving on NWBO.

[DewDiligence]

That’s pretty silly. No one owns ACHN b/c of current earnings.

[girlfriend]

Yes..the chart indicates this but….Zacks is soooo robotic in their research. Look up any Zacks report and you see the same wording and format. They could be correct….we do not know yet.

[maverick_1]

Falling Earnings Estimates Signal Weakness Ahead for Achillion Pharmaceuticals (ACHN)
March 30, 2015
by Zacks Equity Research Published on March 30, 2015
http://www.zacks.com/stock/news/169240/falling-earnings-estimates-signal-weakness-ahead-for-achillion-pharmaceuticals-achn

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Achillion Pharmaceuticals, Inc. (ACHN - Snapshot Report), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in ACHN.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 4 estimates moving down in the past 30 days, compared with no upward revision. This trend has caused the consensus estimate to trend lower, going from a loss of 85 cents a share a month ago to its current level of a loss of 97 cents.

Also, for the current quarter, Achillion Pharmaceuticals has seen 2 downward estimate revisions versus no revision in the opposite direction, dragging the consensus estimate down to a loss of 22 cents a share from a loss of 19 cents over the past 30 days.

The stock also has seen some pretty dismal trading lately, as the share price has dropped 18.7% in the past month.

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Biomedicine sector, you may instead a better-ranked stock Acorda Therapeutics, Inc. (ACOR - Analyst Report) with a Zacks Rank #1 (Strong Buy).

[jay one]

I got in at 10.50 did not think it would fall below 10, now waiting for that pop to $15, hopefully before summer

[DewDiligence]

ACHN’s head of Regulatory Affairs leaving the company on March 31:

http://www.sec.gov/Archives/edgar/data/1070336/000119312515103243/d896253d8k.htm

[mapman1010]

Thanks BSB. it looks ready to pop to the upside.

[Basin Street Blues]

Upcoming Trial Information :

[Basin Street Blues]

Techs $17-$18 in next 34 days

[Basin Street Blues]

New Technical Price Target

Mar 14, 2015 01:54:29 [RCG]

Achillion Pharmaceuticals Inc forms bullish "Continuation
Wedge" chart pattern
Recognia has detected a "Continuation Wedge (Bullish)" chart pattern formed on Achillion Pharmaceuticals Inc (ACHN on NASDAQ). This bullish signal indicates that the price may rise from the close of 11.30 to the range of 17.00 - 18.25. The pattern formed over 34 days which is roughly the period of time in which the target price range may be achieved.
Achillion Pharmaceuticals Inc has a current support price of 11.22 and a resistance level of 12.05.

[Basin Street Blues]

Zacks ..

`Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has witnessed a colossal drop of 0.9% or 141,940 shares in its short figure. The short interest diminution took it from 15,324,965 on February 13,2015 to 15,183,025 on February 27,2015. In terms of floated shares, the short interest was calculated to be 14.6%. The days to cover are 3 given that the daily volume averaged 5,155,358 shares`

Not sure how `colossal` 142k shares is but any reduction is a harbinger of better things to come ..